Investigating the Association Between Fasting Serum Glucose Levels and Cerebral Metabolic Rate for Glucose in Brain Regions Affected by Alzheimer's Disease

Christine Burns,Kewei Chen,Alfred Kaszniak,Wendy Lee,Gene Alexander,Dan Bandy,Adam Fleisher,Richard Caselli,Eric Reiman
DOI: https://doi.org/10.1016/j.jalz.2011.05.152
2011-01-01
Abstract:We proposed the use of regional fluorodeoxyglucose (FDG) positron emission tomography (PET) measurements of the cerebral metabolic rate for glucose (CMRgl) as a pre-symptomatic endophenotype to evaluate genetic and non-genetic risk factors associated with Alzheimer's disease (AD; Reiman PNAS 2005, Reiman NeuroImage 2010). Epidemiological studies have implicated high fasting serum glucose (FSG) levels as a risk factor for a variety of changes in cognition that occur later in life, including cognitive changes in healthy older adults, predementia syndrome, and AD. In this study of healthy older adults, we investigate the association between FSG levels and regional CMRgl, as well as an interaction between higher FSG level and genetic risk for AD. This study aims to test the hypothesis that higher FSG levels in cognitively normal, older adults are associated with lower CMRgl measurements in AD-affected brain regions, and to compare these associations in carriers and non-carriers of the apolipoprotein E (APOE) e4 allele , an established genetic risk factor for late-onset AD. A brain mapping algorithm (SPM8) was used to compute significant correlations between FSG levels and PET CMRgl measurements in 124 healthy, cognitively normal persons 64 ± 6 years of age, including 23 APOE e4 homozygotes (HM), 40 e4 heterozygotes (HT), and 61 e4 non-carriers (NC). Higher FSG levels were significantly correlated with lower CMRgl bilaterally in posterior cingulate, precuneus, parietotemporal, and prefrontal brain regions (p <0.005 uncorrected for multiple comparisons) that have previously been reported to be affected by AD. The correlations were significantly stronger in APOE e4 carriers (HM and HT) than NC in precuneus and parietotemporal areas (p <0.005, uncorrected for multiple comparisons). These results further support the use of FDG-PET in the evaluation of genetic and non-genetic risk factors for AD. Higher FSG levels in older adults may impart a risk for AD within the context of insulin resistance or other metabolic disorders that have been linked to relevant AD pathology. FDG-PET measurements may prove useful in the future evaluation of important pharmaceutical or lifestyle based intervention studies that target glucose control and AD risk in the older adult.
What problem does this paper attempt to address?